Bryn Mawr Capital Management LLC Has $3.94 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Bryn Mawr Capital Management LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 28.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,662 shares of the medical research company’s stock after selling 5,491 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Amgen were worth $3,935,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. BIP Wealth LLC increased its stake in Amgen by 2.6% in the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock valued at $360,000 after purchasing an additional 32 shares during the last quarter. Southland Equity Partners LLC raised its stake in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after buying an additional 34 shares during the last quarter. Acropolis Investment Management LLC raised its stake in shares of Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after buying an additional 34 shares during the last quarter. Opal Wealth Advisors LLC raised its stake in Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 34 shares during the last quarter. Finally, Marino Stram & Associates LLC raised its stake in Amgen by 0.7% in the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock valued at $1,332,000 after purchasing an additional 34 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on AMGN shares. Raymond James initiated coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating for the company. Morgan Stanley decreased their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. The Goldman Sachs Group upped their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Truist Financial restated a “buy” rating and issued a $320.00 price target on shares of Amgen in a report on Friday, April 12th. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Stock Performance

NASDAQ AMGN traded up $0.60 during trading hours on Friday, hitting $269.98. The company had a trading volume of 2,436,947 shares, compared to its average volume of 2,822,655. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The business has a fifty day simple moving average of $275.10 and a 200-day simple moving average of $281.45. The firm has a market cap of $144.81 billion, a P/E ratio of 21.62, a price-to-earnings-growth ratio of 2.54 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. During the same quarter last year, the company posted $4.09 EPS. Amgen’s revenue for the quarter was up 19.8% on a year-over-year basis. Equities analysts predict that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.